Roche's CT-388 Adds Optionality In The GLP Market, But Wait For Dips

分组1 - Roche Holding AG, through its US subsidiary Genentech, presented Phase 2 results for CT-388, a once-weekly dual GLP1/GIP receptor agonist aimed at adults with obesity or overweight without type 2 diabetes [1] - The trial results indicate the potential effectiveness of CT-388 in managing weight among the target population, which could position Roche favorably in the obesity treatment market [1]